SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-13-063257
Filing Date
2013-08-13
Accepted
2013-08-13 16:06:33
Documents
11
Period of Report
2013-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a13-12428_110q.htm 10-Q 735487
2 EX-10.3 a13-12428_1ex10d3.htm EX-10.3 117363
3 EX-31.1 a13-12428_1ex31d1.htm EX-31.1 10549
4 EX-31.2 a13-12428_1ex31d2.htm EX-31.2 10360
5 EX-32.1 a13-12428_1ex32d1.htm EX-32.1 7045
  Complete submission text file 0001104659-13-063257.txt   6768158

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT mrtx-20130630.xml EX-101.INS 658978
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20130630.xsd EX-101.SCH 42594
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20130630_cal.xml EX-101.CAL 44892
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20130630_def.xml EX-101.DEF 109480
10 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT mrtx-20130630_lab.xml EX-101.LAB 501673
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20130630_pre.xml EX-101.PRE 229157
Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 131033143
SIC: 2834 Pharmaceutical Preparations